Dr. Jeremy M. Merritt is a Director at Eli Lilly and Co. in the small molecule design and development organization (SMDD). He currently leads the Particle Design Lab (PDL) responsible for crystallization process development with a focus on designing the commercial process and enabling physical property attributes for successful integration with drug product processing with emphasis on continuous processing. Prior to the PDL he was a contributor in growing the modeling and simulation capability group for SMDD with emphasis on scale-up and impurity control. He also advanced the mechanistic understanding behind salt disproportionation in the solid-state through modeling efforts. Jeremy received his PhD in physical chemistry from the University of North Carolina at Chapel Hill and spent one month as an invited researcher at the Fritz-Haber Institute of the Max-Plank Society in the department.
: Control, is it achievable in amorphous or poorly crystalline peptide isolations?